IMAB - Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
- Zai will have greater China rights to two Blueprint next-gen EGFR candidates aimed at non-small cell lung cancer (NSCLC), which Blueprint says have first-in-class potential.
- Earlier this year, I-Mab started a pivotal China Phase III trial of eftansomatropin alfa as a weekly treatment for pediatric growth hormone deficiency (PGHD).
- Earlier this week, Ascletis announced it had added global rights to its agreement with Suzhou Alphamab for the PD-L1 in China viral disease indications.
For further details see:
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million